Search
Dasiprotimut-T
go.drugbank.com/drugs/DB17287ExperimentalDasiprotimut-T is a personalized therapeutic vaccine against B-cell lymphomas.[A254701] It has been investigated in clinical trials.
LV305
go.drugbank.com/drugs/DB17288InvestigationalLV305 is a lentiviral vector encoding NY-ESO-1 gene. LV305 is an active component of CMB305 along with [G305].[L47346]
Leuvectin
go.drugbank.com/drugs/DB17303InvestigationalLeuvectin (formerly known as VCL-1102) is a component of gene therapy along with cationic lipid 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium bromide/dioleyl-phosphatidyl-ethanolamine (DMRIE
CAR BCMA-CS1
go.drugbank.com/drugs/DB17313ExperimentalCAR BCMA-CS1 is a lentiviral transfected chimeric antigen receptor (CAR) T-cell therapy modified to target B-cell maturation antigen and CS1.
ICG-136
go.drugbank.com/drugs/DB17343ExperimentalICG-136 is a compound chimeric antigen receptor (cCAR) T-cell therapy developed by iCell Gene Therapeutics. It was investigated for the treatment of acute myeloid leukemia.
Obecabtagene autoleucel
go.drugbank.com/drugs/DB17362ApprovedInvestigationalObecabtagene autoleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy with a fast off-rate binding profile for CD19.
Synonyms: A CHIMERIC ANTIGEN RECEPTOR (CAR) CONSISTING O, AUTOLOGOUS CD4+ AND CD8+ T CELLS, ENRICHED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) OBTAINED BY APHERESIS TRANSDUCED EX VIVO WITH A NON-REPLICATING, SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODINGAUM-601
go.drugbank.com/drugs/DB17382ExperimentalAUM-601 is a highly selective pan-TRK(tropomyosin receptor kinase). It is currently being investigated in clinical trials for the treatment of cancer.
Gemogenovatucel-T
go.drugbank.com/drugs/DB17412InvestigationalGemogenovatucel-T is a bi-shRNA furin/Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented autologous tumour cell vaccine. … Furin is a convertase involved in the activation of TGFβ-1 and TGFβ-2.[A255163] Gemogenovatucel-T is being investigated in the treatment of various cancers.
Trastuzumab botidotin
go.drugbank.com/drugs/DB17413ExperimentalA166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (trastuzumab) via a stable protease-cleavable
BS-001
go.drugbank.com/drugs/DB17415InvestigationalBS-001 is a recombinant oncolytic herpes simplex virus type II (OH2) therapeutic injection (Vero cell) for human use (rHSV2hGM-CSF).